Price T Rowe Associates Inc Chinook Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.66 - $38.58 $230,973 - $477,543	-12,378 Reduced 43.7%	15,944 $613,000
Q1 2023 May 15, 2023	BUY	$21.53 - $26.8 $18,537 - $23,074	861 Added 3.14%	28,322 $657,000
Q4 2022 Feb 14, 2023	BUY	$18.63 - $27.35 $19,282 - $28,307	1,035 Added 3.92%	27,461 $719,000
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $462,719 - $617,575	26,426 New	26,426 $520,000
Q4 2021 Feb 14, 2022	SELL	$10.69 - $16.83 $127,136 - $200,159	-11,893 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $136,769 - $176,729	11,893 New	11,893 $152,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.